{
    "nctId": "NCT02305641",
    "briefTitle": "An Observational Study of Kadcyla Safety in Breast Cancer",
    "officialTitle": "Post-Marketing Surveillance of Kadcyla in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 563,
    "primaryOutcomeMeasure": "Safety (composite outcome measure): Incidence of serious adverse events (SAEs), adverse drug reactions (ADRs); unexpected adverse events and ADRs; expected ADRs; non-serious ADRs",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are administered with Kadcyla at physician's discretion will be registered for this study. The use of Kadcyla in the patients must fall into the approved indication in Korea.\n\nExclusion Criteria:\n\n* Patients not receiving treatment for breast cancer with Kadcyla according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling.\n* A pediatric patient (age \u226418 years)\n* Hypersensitivity for Kadcyla or any ingredient in this product",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}